Wood M. Pharmacokinetic drug interactions in anaes- thetic practice. Clin Pharmacokinet 1991;21:285-307.Wood, M., 1991, Pharmacokinetic drug interactions in anaesthetic practice. Clinical Pharmacokinetics, 21, 285±307.Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet...
in part because the high incidence of toxicity and treatment failure, and empirical dosing methods, obscure the recognition of possible interactions. Awareness on the part of the clinician and more extensive pharmacokinetic investigation
These drugs are indicated in a variety of infections and are often combined with other drug therapies, thus creating the potential for pharmacokinetic interactions. Macrolides can both inhibit drug metabolism in the liver by complex formation and inactivation of microsomal drug oxidising enzymes and ...
Both acute and chronic ethanol use can cause transient changes to many physiologic responses in different organ systems such as hypotension and impairment of motor and cognitive functions, resulting in both pharmacokinetic and pharmacodynamic interactions. Evaluating drug interactions with long-term use of...
During drug development, it is essential to gather information about the change of clinical exposure of a drug (object) due to the pharmacokinetic (PK) drug-drug interactions (DDIs) with another drug (precipitant). While many natural language processing (NLP) methods for DDI have been published...
Therefore, evaluating the drug–drug interaction (DDI) potential associated with MMAE is important in the clinical development of ADCs. The objective of this work was to build a physiologically based pharmacokinetic (PBPK) model to assess MMAE–drug interactions for vc-MMAE ADCs. Methods A PBPK ...
CYP3A was involved in approximately two-thirds of all drug-drug interactions (DDIs). Transporters (alone or with enzymes) participated in about half of all interactions, but most of these were weak-to-moderate interactions. When considered as victims, eight new molecular entities (NMEs; ...
Topics discussed include analysis of assess cytochrome P450 mediated drug–drug interactions; use of pharmacokinetic phenotyping for predicting drug–drug interactions; and clinical relevance of the interactions of therapeutic drugs.doi:10.1002/cpt.772...
Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990 Jun; 18(6): 472–84 ArticlePubMedCASGoogle Scholar Okusanya O, Forrest A, DiFrancesco R, et al. Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Che...
Data concerning the breakpoints established for the minimum serum concentrations of itraconazole are included, and the most relevant justifications for drug monitoring are cited. 展开 关键词: Drug interactions itraconazole therapeutic drug monitoring.